1. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
- Author
-
Narendranath, Epperla, Jeffrey M, Switchenko, Veronika, Bachanova, James N, Gerson, Stefan K, Barta, Max J, Gordon, Alexey V, Danilov, Natalie Sophia, Grover, Stephanie P, Mathews, Madelyn, Burkart, Reem, Karmali, Yazeed, Sawalha, Brian T, Hill, Nilanjan, Ghosh, Steven I, Park, David A, Bond, Mehdi, Hamadani, Timothy S, Fenske, Peter, Martin, Jin, Guo, Mary-Kate, Malecek, Brad S, Kahl, Christopher R, Flowers, Brian K, Link, Lawrence D, Kaplan, David J, Inwards, Andrew, Feldman, Eric D, Hsi, Kami, Maddocks, Kristie, Blum, Namcy L, Bartlett, James R, Cerhan, John P, Leonard, Thomas M, Habermann, Matthew J, Maurer, and Jonathon B, Cohen
- Subjects
Hematology - Abstract
The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought to evaluate the impact of DTI on outcomes in MCL using 3 large datasets (1) the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource, (2) patients enrolled in the ALL Age Asthma Cohort/CALGB 50403, and (3) a multisitecohort of patients with MCL. Patients were a priori divided into 2 groups, 0 to 14 days (short DTI) and 15 to 60 days (long DTI). The patients in whom observation was deemed appropriate were excluded. One thousand ninety-seven patients newly diagnosed with MCL and available DTI were included in the study. The majority (73%) had long DTI (n=797). Patients with short DTI had worse eastern cooperative oncology group performance status (ECOG PS ≥2), higher lactate dehydrogenase, bone marrow involvement, more frequent B symptoms, higher MCL International Prognostic Index (MIPI ≥6.2), and were less likely to receive intensive induction therapy than long DTI group. The median progression-free survival (2.5 years vs 4.8 years, p
- Published
- 2023